Breakthroughs in Generalized Myasthenia Gravis

Breakthroughs in Generalized Myasthenia Gravis is organized by Vindico Medical Education and will be held on Feb 26, 2025.

Overview:
Ready to level up your generalized myasthenia gravis (gMG) management skills? This CME webinar offers neurologists a deep dive into the latest advancements in gMG care. Explore how a better understanding of the disease burden can drive smarter clinical decisions and discover how neonatal Fc receptor inhibitors are reshaping long-term treatment strategies. With insights on the pathophysiology and exploration of real-world evidence, you’ll gain the necessary tools to personalize care and achieve better, lasting outcomes for your patients. Following the webinar, join us for the AfterShow Q&A: a live breakout session! Connect directly with faculty, engage in discussions, and ask individualized questions in a collaborative and dynamic environment.

Agenda:
Introduction

Understanding Clinical Presentation and Disease Burden

Hans D. Katzberg, MD

Patient Journey: Part 1 – Assessing Disease Burden and Severity

Nicholas Silvestri, MD, with panel discussion

Understanding Disease Pathophysiology and Limitations of Conventional Therapies

Nicholas Silvestri, MD

Patient Journey: Part 2 – Managing Adverse Effects and Re-evaluating Treatment Based on Pathophysiology

Nicholas Silvestri, MD, with panel discussion

Targeted Treatment Approaches: Current and Emerging FcRn Antagonists

Vera Bril, MD

Patient Journey: Part 3 – Integrating FcRn Inhibitors Into Short- and Long-Term Management Plans

Nicholas Silvestri, MD, with panel discussion

Conclusion

After-Show Question & Answer

Join us for the AfterShow Q&A—a live breakout session where you will connect directly with faculty, engage in discussions, and ask your questions. Cameras and microphones are encouraged!

Learning Objectives:
Upon successful completion of this activity, participants should be better able to:

• Recognize how appropriate assessment of disease burden can guide clinical decision-making for patients with gMG.
• Identify how the pathophysiology of gMG informs treatment selection, highlighting the limitations of standard-of-care therapies in addressing disease mechanisms.
• Evaluate the latest clinical data on neonatal Fc receptor (FcRn) inhibitors for the treatment of patients with gMG.
• Assess the role of FcRn inhibitors in long-term management strategies for patients with gMG to improve sustained patient outcomes.